AdAlta (ASX:1AD) share price rockets 31% on United States FDA update

The AdAlta Ltd (ASX:1AD) share price is rocketing today following the positive news on its drug trials. Here's all the details.

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AdAlta Ltd (ASX:1AD) share price is rocketing today following the positive news on its drug trials. In mid-morning trade, the biotech company's share price is soaring 31.4% higher to 23 cents.

However, at the time of writing, the AdAlta share price has retreated slightly to 20 cents, up 14.29%. Also, it's worth noting that the AdAlta share price reached a 52-week high of 26.5 cents in the opening minutes of trade.

Quick take on AdAlta

Established in 2006, AdAlta is a clinical-stage biotechnology company. The company's focus is on researching and developing protein-based therapies. Thus, AdAlta utilises a range of unique compounds, known as i-bodies, to create a pipeline of drugs to treat serious diseases. This includes idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases.

What did AdAlta announce?

The AdAlta share price is racing higher as investors are fighting to get a parcel of its shares.

In this morning's release, AdAlta advised it has been granted Orphan Drug Designation (ODD) from the United States Food and Drug Administration (FDA). In particular, this is for its lead product candidate AD-214.

The Orphan Drug Act, created by the FDA, aims to motivate biopharmaceutical companies in developing potential medicines for rare or 'orphan' diseases. The ODD provides preferential treatment that enhances a company's standing with the agency. It is estimated that rare and orphan diseases affect around 200,000 people in the United States alone.

The welcomed decision enables the company to receive special benefits of achieving incentivised targets. This includes eligibility for seven years of market exclusivity after FDA approval and discounted tax credits of 50% of drug testing costs. Benefits also include additional protocol assistance, reduced review times, and specific marketing authorisation application fees waived.

This follows the company's previous ODD for AD-114, the predecessor molecule to AD-214.

AdAlta noted that receiving ODD will bring extra economic value for AD-214. This will flow onto its future commercial partners.

About the AdAlta share price

In the past year, the company's shares have accelerated to give investors a gain of more than 180%. In March, the AdAlta share price traded for as little as 4 cents, before gradually increasing over the 11 months. However today, the biotech's shares reached a 52-week high of 26.5 cents.

Based on the current share price, AdAlta commands a market capitalisation of roughly $51 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a miserly session for investors today.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Opinions

Too high? These 2 ASX shares might be due for a correction

These popular blue chips are looking dicey to me.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares could rise 20% to 35%

These shares are being tipped to deliver market-beating returns by analysts.

Read more »

Keyboard button with the word sell on it.
Broker Notes

8 ASX All Ords stocks downgraded to sell ratings

Find out which shares are out of favour with the experts.

Read more »

Woman smiling whilst shopping in a clothing store.
Dividend Investing

Why this quality ASX 300 dividend stock is tipped to surge 54%

A leading fund manager forecasts significant outperformance from this quality ASX 300 dividend stock.

Read more »

A group of businesspeople clapping.
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in June

These stocks could be best buys this month according to the broker.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Market News

Why Clarity, Coronado Global, Iperionx, and Lynas shares are roaring higher today

These shares are having a strong session on Thursday. Why are investors buying them?

Read more »

A woman looks questioning as she puts a coin into a piggy bank.
Opinions

The ASX 200 is approaching its all-time high. Here's why I'm not buying shares

I'm not seeing what the broader market is.

Read more »